Skip to main content
. 2022 Oct;23(10):3371–3378. doi: 10.31557/APJCP.2022.23.10.3371

Table 3.

Overall Survival in the Two Groups

CG group PC group
(n=253) (n=68)
Median survival time, months 9.6 9
1-year survival 38 33
2-year survival 16 17
3-year survival 8 6
4-year survival 2 2
5-year survival 0 0

CG, carboplatin + gemcitabine; PC, paclitaxel + carboplatin